ACTRN12614000098639已完成1 期
Determining the maximum tolerated dose of prescribed physical activity (in the form of walking) for people with severe osteoarthritis of the knee in the community in terms of safety and feasibility
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Jason Wallis
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 50 Years 至 o limit（—）
- 性别
- All
入选标准
- •(1) Adult aged at least 50 years and living independently in the community;
- •(2) diagnosed with moderate-to-severe knee osteoarthritis rated as grade III or IV;
- •(3) able to understand English;
- •(4) able to participate safely in the moderate-intensity physical activity trial using the 7-item Physical Activity Readiness Questionnaire.
排除标准
- •(1) live in supported accommodation such as a nursing home;
- •(2) they report their daily resting level of pain to be 9 or 10 on an 11 point Numerical Pain Rating Scale. This level of pain may be indicative of a more serious pathology such as acute or inflammatory condition;
- •(3) high or very high levels of psychological distress as measured by the Kessler 10 questionnaire with a K10 score > 21;
- •(4) have an intellectual or mental impairment as measured by the Short Portable Mental Status Questionnaire with a score of 7 or less;
- •(5) have a systemic arthritic condition such as rheumatoid arthritis;
- •(6) have a neurological condition such as Parkinson’s disease or stroke that affects walking;
- •(7) had knee surgery or intra-articular corticosteroid injection within past six months;
- •(8) currently (within four weeks) using oral corticosteroids.
研究者
相似试验
已完成
1 期
Prescribing physical activity for patients with hip fracture during rehabilitatioHip fracturePhysical Medicine / Rehabilitation - PhysiotherapyInjuries and Accidents - FracturesACTRN12613000828729icholas Taylor30
已完成
1 期
phase I clinical trial of topical Carbon Selenium Complexheat burn injury.Burns and corrosions of external body surface, specified by siteT20, T21,IRCT138811253267N1Parsroos Company15
进行中（未招募）
不适用
Assessment of the Maximal Tolerated Dose of a Microencapsulated House Dust Mite (Dermatophagoides pteronyssinus and Dermatophagoides farinae) Extract (MHDME) in Subjects with House Dust Mite Allergy in a Randomized, Double-Blind, Placebo-Controlled Study - DME_01EUCTR2007-003930-41-DECuralogic A/S30
进行中（未招募）
不适用
Assessment of the Maximal Tolerated Dose of a Microencapsulated Grass (Phleum pratense) Pollen Extract (MGPE) in Subjects with Grass Pollen Allergy in a Randomized, Double-Blind, Placebo-Controlled Study - GPE 02Treatment of seasonal allergic rhinitis to grass pollen.EUCTR2006-004222-93-DECuralogic A/S30
进行中（未招募）
不适用
Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 yearsEUCTR2011-001292-39-HUInstitut de Recherches Internationales Servier90